



Progress in Cardiovascular Diseases

Publication information: *Progress in Cardiovascular Diseases* (ISSN: 0033-0620) is published bimonthly by Elsevier 230 Park Avenue, Suite 800, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices.

USA POSTMASTER: Send address changes to *Progress in Cardiovascular Diseases*, Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA.

Annual subscription rates: United States and possessions: individual, \$329.00. All other countries: individual, \$507.00. For all areas outside the United States and possessions, there is no additional charge for surface delivery. Students and residents: United States and possessions: \$157.00; all other countries: \$262.00. To receive student /resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received.

Orders, claims, and journal inquiries: Please visit our Support Hub page <https://service.elsevier.com> for assistance.

Advertising information: Advertising orders and inquiries can be sent to: USA, Canada, and South America, Aileen Rivera, Elsevier, 230 Park Avenue, Suite 800, New York, NY 10169; phone 212-633-3721; email: a.rivera@elsevier.com.

Reprints: To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169; E-mail: reprints@elsevier.com.

Guide for Authors: For a full and complete Guide for Authors, please go to: www.elsevier.com/wps/locate/issn/0033-0620.

Editorial correspondence and articles for original publication in this journal (reviews suitable for symposia, seminars, or editorials) should be addressed to Carl J. Lavie, MD, Editor-in-Chief, Ochsner Clinical School, The University of Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, LA 70121. Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Publisher. The Publisher will not refuse any reasonable request by the author for permission to reproduce any of his or her contributions to the journal. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at <http://www.elsevier.com/trackarticle>. You can also check our Author FAQs at <http://www.elsevier.com/authorFAQ> and/or contact Customer Support via <http://support.elsevier.com>.

Funding body agreements and policies: Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

© 2019 Elsevier Inc. All rights reserved. This journal and the individual contributions contained in it are protected under copyright by Elsevier Inc., and the following terms and conditions apply to their use: **Photocopying:** Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA). **Derivative Works:** Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions). **Electronic Storage or Usage:** Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. **Notice:** No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

The contents of *Progress in Cardiovascular Diseases* are indexed in CINAHL.

Ⓢ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper)